Osprey Private Wealth LLC Has $4.37 Million Stake in Stryker Corporation $SYK

Osprey Private Wealth LLC lifted its position in shares of Stryker Corporation (NYSE:SYK) by 32.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,889 shares of the medical technology company’s stock after purchasing an additional 3,398 shares during the period. Osprey Private Wealth LLC’s holdings in Stryker were worth $4,373,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Varma Mutual Pension Insurance Co increased its holdings in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after purchasing an additional 5,100 shares during the period. QRG Capital Management Inc. boosted its stake in shares of Stryker by 7.4% in the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after buying an additional 4,186 shares during the period. Swedbank AB grew its position in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after buying an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after buying an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Barclays decreased their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Robert W. Baird set a $385.00 price target on Stryker in a research note on Friday, May 1st. JPMorgan Chase & Co. cut their price objective on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity

In related news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company’s stock.

Stryker Stock Down 0.7%

Shares of SYK opened at $338.80 on Friday. The firm has a 50 day simple moving average of $324.61 and a two-hundred day simple moving average of $333.57. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a market cap of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the business posted $3.13 EPS. The company’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.